TL;DR
This paper introduces a novel high-throughput screening method using next-generation sequencing to identify antibiotic targets by tracking the competitive fitness of essential gene knockdowns. They discovered a new broad-spectrum antibacterial compound, C109, which targets the essential bacterial cell division protein FtsZ, offering a promising avenue for developing new antibiotics against challenging pathogens.
What Problem Does This Paper Address?
The relentless rise of antibiotic resistance necessitates the discovery of new drugs with novel mechanisms of action. A major bottleneck in this process is identifying the specific molecular target of a potential antibiotic. Traditional methods can be slow and laborious. While next-generation sequencing (NGS) has revolutionized genetic screening, its potential for rapidly identifying antibiotic targets in bacteria hasn't been fully exploited. This paper addresses this by developing and applying an NGS-based competitive fitness assay to efficiently pinpoint the targets of novel antibacterial compounds, specifically focusing on difficult-to-treat pathogens like Burkholderia cenocepacia.
Methods
The core innovation is a competitive fitness assay coupled with transposon sequencing (Tn-seq). They created a library of Burkholderia cenocepacia mutants, each with a knockdown of an essential gene. This library was then grown in the presence of a sub-inhibitory concentration of an antibiotic. If a specific gene knockdown made the bacteria hypersusceptible to the antibiotic, that mutant would be depleted from the population. By sequencing the transposon insertion sites in the surviving bacteria, they could quantify the relative abundance of each mutant and identify those that were significantly depleted. This allowed them to infer the essential gene targeted by the antibiotic.
To further validate the target and understand the mechanism of action, they employed:
- Fluorescence microscopy: To visualize the localization of essential cell division proteins (like FtsZ) in the presence of the compound.
- Biochemical assays: To directly test the compound's effect on the purified target protein's enzymatic activity (GTPase and polymerization for FtsZ).
- Morphological screening: Observing changes in bacterial cell shape under antibiotic treatment.
- Genetic manipulation: Creating specific gene knockdowns or overexpression strains to confirm susceptibility.
Datasets
The primary dataset used was generated from the Illumina sequencing of transposon insertions from the Burkholderia cenocepacia mutant library after exposure to the compound C109 and a control antibiotic (novobiocin). This dataset allowed for the quantitative assessment of mutant depletion.
The paper also references and implicitly uses data from:
- Publicly available essential gene sets for B. cenocepacia to construct the mutant library.
- Existing E. coli strains expressing GFP-fusions of cell division proteins for microscopy studies.
- Clinical isolates of various Gram-negative and Gram-positive bacteria for broad-spectrum activity testing.
Key Insights and Ideas
- NGS-based competitive fitness is a powerful tool for target identification: This study demonstrates that coupling Tn-seq with essential gene knockdowns can rapidly and efficiently identify antibiotic targets, overcoming limitations of previous chemogenomic approaches.
- C109 is a novel inhibitor of bacterial cell division: The compound C109, initially identified through screening, was found to specifically disrupt the formation of the divisome, the complex machinery responsible for bacterial cell division.
- FtsZ is a critical target for C109: Through a combination of genetic and biochemical evidence, the paper strongly implicates FtsZ, an essential protein that forms the Z-ring, as the direct target of C109. This is significant because FtsZ is a validated antibacterial target, but inhibitors are lacking, especially for Gram-negative bacteria.
- C109 has broad-spectrum activity and potential for combination therapy: The compound shows efficacy against a range of challenging pathogens, including Mycobacterium abscessus, and exhibits additive effects with existing antibiotics, suggesting its utility in combating multi-drug resistant infections.
Key Results
- The Tn-seq assay successfully identified known targets for novobiocin (gyrB) and revealed hypersusceptible mutants for C109, pointing towards the cell division machinery.
- Morphological analysis showed that C109 treatment induced filamentation, a hallmark of cell division inhibition, and this phenotype was mimicked by knockdowns of genes within the dcw cluster, which includes ftsZ.
- Fluorescence microscopy demonstrated that C109 disrupts the proper midcell localization of essential divisome proteins like FtsZ-GFP, FtsA-GFP, and FtsW-GFP.
- Biochemical assays confirmed that C109 directly inhibits the GTPase activity of purified B. cenocepacia FtsZ in a non-competitive manner and also inhibits FtsZ polymerization.
- C109 exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including M. abscessus, and effectively cleared B. cenocepacia infections in a C. elegans model.
- C109 showed additive interactions with several common antibiotics, suggesting potential for combination therapies.
Limitations and Future Work
- Non-protein targets: The authors acknowledge that their genetic screen is best suited for identifying protein targets and might miss compounds that act on non-proteinaceous targets.
- Solubility: C109 has poor aqueous solubility, which could limit its utility for systemic administration. The authors mention that derivatives synthesized so far have not shown improved solubility.
- Inhaled therapy potential: Due to its small size and lipophilic nature, C109 is proposed as a candidate for inhaled therapy for respiratory infections, particularly in cystic fibrosis patients. Further development of formulations for this route is suggested.
- Combination therapy optimization: While additive interactions were observed, further work is needed to explore synergistic combinations and understand the underlying mechanisms, especially given the lack of synergy with some common antibiotics.
- Resistance development: The absence of spontaneous target-related mutations upon C109 exposure is promising, but further investigation into potential resistance mechanisms is warranted for long-term therapeutic use.
Summary updated